Truist initiated coverage of Apogee Therapeutics (APGE) with a Hold rating and $83 price target The firm believes Apogee is an “attractive emerging player” in immunology inflammation with a potentially disruptive atopic dermatitis treatment. However, the stock’s near-term setup is challenging, with a “high bar for meaningful” upside from the Phase 2 Part A maintenance data expected by month-end, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Buy Rating on APGE Shares Driven by Zumilokibart’s Differentiated Long-Acting Efficacy and Scarcity Value in Atopic Dermatitis
- Apogee Therapeutics: Strong Phase II AD Data and 2026 Readouts Underpin Buy Rating and Potential to Displace JAK-Based Regimens
- Citi adds ‘upside 30-day catalyst watch’ on Apogee Therapeutics
- Apogee Therapeutics price target raised to $95 from $90 at Wedbush
- Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability